ROTTERDAM, the Netherlands, July 11, 2024 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round. This round includes a new investor InnovationQuarter and continued support from existing investors: Van Herk Ventures, Thuja Capital, Swanbridge Capital and Erasmus MC O&O Holdings, bringing Pan Cancer T’s total funding to approximately €11 million.

荷兰鹿特丹，2024年7月11日（环球通讯社）--Pan Cancer T B.V.是一家开创性的生物技术初创公司，开发用于实体癌治疗的下一代T细胞疗法，已成功完成了425万欧元的种子延长期。这一轮包括新的投资者创新季度（investor InnovationQuarter），以及现有投资者（Van Herk Ventures、Thuja Capital、Swanbridge Capital和Erasmus MC O＆O Holdings）的持续支持，使泛癌症T的总资金达到约1100万欧元。

As a result, Investment Manager of InnovationQuarter Nina Satih will take a Supervisory Board observer role. The Seed Extension Round will allow Pan Cancer T to complete preclinical studies for its lead TCR-T cell product, PCT1:CO-STIM, and progress CMC activities, thereby creating value and derisking the project.

因此，InnovationQuarter的投资经理Nina Satih将担任监事会观察员。种子扩展回合将允许泛癌T完成其主要TCR-T细胞产品PCT1:CO-STIM的临床前研究，并推进CMC活动，从而创造价值并衍生该项目。

The funding will also support progression of earlier-stage pipeline projects targeting colorectal and ovarian cancers and the development of a second next generation engineering approach. “We are delighted to have closed this financing round with the support of InnovationQuarter and our existing investors,” says Rachel Abbott, CEO of Pan Cancer T.

该资金还将支持针对结直肠癌和卵巢癌的早期管道项目的进展，以及第二代下一代工程方法的开发。“我们很高兴在InnovationQuarter和现有投资者的支持下结束了这轮融资，”泛癌症T的首席执行官雷切尔·阿伯特（RachelAbbott）表示。

“This enables us to advance our lead product toward the clinic, offering new hope for patients with triple negative breast cancer. It also provides a firm foundation to secure a Series A round within the coming year and seek business development partnerships with Biotech and Pharma collaborators to further develop our assets, including our TCR:CO-STIM platform that is applicable to other TCRs and tumour indications.” “InnovationQuarter is proud to invest in Pan Cancer T, contributing to the development of state-of-the-art cell therapies to combat hard-to-treat cancers”, says Kees Recourt, Senior Investment Manager at InnovationQu.

“这使我们能够将领先产品推向临床，为三阴性乳腺癌患者提供新的希望。这也为在未来一年内确保a轮系列奠定了坚实的基础，并寻求与生物技术和制药合作伙伴的业务发展伙伴关系，以进一步开发我们的资产，包括我们的TCR:CO-STIM平台，该平台适用于其他TCR和肿瘤适应症。”“InnovationQuarter很骄傲地投资于泛癌T，为开发最先进的细胞疗法以对抗难以治疗的癌症做出了贡献”，InnovationQu的高级投资经理Kees Recurt说。